ArticleAmerican journal of cancer research2016
MiR-101 targets USP22 to inhibit the tumorigenesis of papillary thyroid carcinoma.
Article in American journal of cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pooled it
- Integrating miRNA profiling and machine learning for improved thyroid cancer diagnosis.Frontiers in oncology · 2026Article
- A narrative review of papillary thyroid carcinoma-related long non-coding RNAs and their relevance to malignant tumors.Translational cancer research · 2025Review
- Contribution of microRNA-30d to the prevention of the thyroid cancer occurrence and progression: mechanism and implications.Apoptosis : an international journal on programmed cell death · 2023Article
- Profile of MicroRNAs Associated with Death Due to Disease Progression in Metastatic Papillary Thyroid Carcinoma Patients.Cancers · 2023Article
- Transcription factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expression.Cell communication and signaling : CCS · 2022Article
- Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.Journal of oncology · 2022Review
- LncRNA XIST Promotes Migration and Invasion of Papillary Thyroid Cancer Cell by Modulating MiR-101-3p/CLDN1 Axis.Biochemical genetics · 2021Article
- Upregulation of LINC01426 promotes the progression and stemness in lung adenocarcinoma by enhancing the level of SHH protein to activate the hedgehog pathway.Cell death & disease · 2021Article
- MiR-4500 Regulates PLXNC1 and Inhibits Papillary Thyroid Cancer Progression.Hormones & cancer · 2019Article
- Ubiquitin-specific peptidase 22 promotes proliferation and metastasis in human colon cancer.Oncology letters · 2019Article
- MicroRNA-101 Targets CXCL12-Mediated Akt and Snail Signaling Pathways to Inhibit Cellular Proliferation and Invasion in Papillary Thyroid Carcinoma.Oncology research · 2019Article
- The proliferation and invasion of osteosarcoma are inhibited by miR-101 via targetting ZEB2.Bioscience reports · 2019Article
- Diagnostic and prognostic implications of serum miR-101 in osteosarcoma.Cancer biomarkers : section A of Disease markers · 2018Article
- MiR-101: a potential therapeutic target of cancers.American journal of translational research · 2018Review
- microRNA-9 functions as a tumor suppressor in colorectal cancer by targeting CXCR4.International journal of clinical and experimental pathology · 2018Article
- The prognostic value of decreased miR-101 in various cancers: a meta-analysis of 12 studies.OncoTargets and therapy · 2017Article
- Alpinumisoflavone suppresses tumour growth and metastasis of clear-cell renal cell carcinoma.American journal of cancer research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence suggests that microRNA-101 (miR-101) is involved in the progression of various human cancers, including papillary thyroid carcinoma (PTC). However, the biological functions of miR-101 and underlying molecular mechanisms in PTC remain largely unknown. In this study, we demonstrated that miR-101 underexpression in PTC tissue was associated with lymph node metastasis and poor prognosis of PTC patients. MiR-101 reduced PTC cell proliferation, apoptosis resistance, and invasion. Ubiquitin-specific protease 22 (USP22) was confirmed as a direct target of miR-101. USP22 restoration attenuated the inhibitory effects of miR-101 on PTC malignant traits in vitro. In vivo, miR-101 overexpression or USP22 depletion reduced the tumorigenesis of PTC. Overall, our findings provide new insight into the mechanism of PTC inhibition by miR-101, suggesting the potential of miR-101 as a therapeutic target in PTC patients.
Indexed as
Identifiers
27904772PMC5126274W2560015040What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.